Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

r placebo (n=118). Significantly more patients in the desvenlafaxine succinate group responded to treatment compared with the placebo group (51 percent vs. 32 percent, respectively) at the final study evaluation. When individual items from the HAM-D17 were analyzed, desvenlafaxine succinate patients experienced a statistically significant improvement in depressed mood, psychic anxiety, general somatic symptoms and suicidal thoughts. Treatment-emergent adverse events reported in this study were consistent with the SNRI class and included nausea, dry mouth, insomnia, somnolence, sweating, anorexia (loss of appetite), tremor and impotence.

About Desvenlafaxine

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a potential treatment for adult men and women with MDD. Wyeth submitted a New Drug Application (NDA) for MDD on December 22, 2005. The Company also has filed an NDA for vasomotor symptoms (VMS) associated with menopause and expects a U.S. Food and Drug Administration (FDA) action letter in the third quarter of 2007. If approved, desvenlafaxine will be the first and only non-hormonal medicine for the treatment of VMS associated with menopause. Wyeth is a leader in both neuroscience and women's health care.

Wyeth discovered and developed the first SNRI approved by the FDA, which currently is the most widely used antidepressant in the world. Desvenlafaxine represents Wyeth's latest efforts and continued commitment to developing therapies to help improve the lives of patients suffering from mental health disorders.

According to a large depression trial funded by the National Institute of Mental Health, only 28 percent of patients with depression achieved remission with initial antidepressant treatment. This leaves a large percentage of patients still suffering from depression. Clearly, additional medicines are needed for treating MDD.

About Antidepressants

Antidepressants increased the risk of s
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... N.Y., Feb. 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: ... following investor conferences: , Citi 2012 Global Healthcare ... 28, 2012 , RBC Capital Markets, Healthcare Conference ... 2012 The sessions may be accessed through ...
... PHILADELPHIA, Pennsylvania and WALTHAM, Massachusetts, February 21, 2012 ... clinical decision support content and analytics tools into ... Elsevier , a world-leading provider of scientific, ... PatientKeeper ®, the leading provider of physician ...
Cached Medicine Technology:Regeneron Announces February 2012 Investor Conference Presentations 2Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 2Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 3Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 4
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... more accurate in early tests , , WEDNESDAY, Feb. 18 ... the widely used anticoagulant warfarin safer by predicting the ... U.S. Food and Drug Administration estimates that 2 million ... that can cause strokes. Reasons range from implantation of ...
... Products for Pregnant Women Creates a Buzz in Hollywood--WESTPORT, ... full-swing, Beaute de Maman , a unique line ... the pregnant woman by an obstetrician, has made it ... Penelope Ann Miller, Salli Richardson-Whitfield ( "Eureka" ), Chyler ...
... /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the year ... million, or 11 cents per share, on revenues of $22.4 million ... per share, on revenues of $31.8 million in the previous year. ... a net income of $2.7 million, or 3 cents per share, ...
... women had no survival advantage over others , , ... smoke have higher death rates than low-paid nonsmokers of ... conclude that smoking may be a greater cause of ... found that smoking cancels out the survival advantage women ...
... New research finds misdiagnosis risk goes up as age goes ... boy complaining of numbness at a Detroit emergency room was ... A 24-year-old woman with sharp pain in her left eye ... by ER doctors that she had a migraine. , And ...
... St. Luke,s Medical Center Discovers Way to Fight ... 18 Researchers at Aurora St. Luke,s Medical ... unusual, but serious, side effect from natalizumab (Tysabri(R)), ... effect is a brain virus called progressive multifocal ...
Cached Medicine News:Health News:Genetics May Help Fine-Tune Warfarin Dosage 2Health News:Genetics May Help Fine-Tune Warfarin Dosage 3Health News:Genetics May Help Fine-Tune Warfarin Dosage 4Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 2Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 3Health News:Westaim announces 2008 year-end results 2Health News:Westaim announces 2008 year-end results 3Health News:Westaim announces 2008 year-end results 4Health News:Westaim announces 2008 year-end results 5Health News:Westaim announces 2008 year-end results 6Health News:Westaim announces 2008 year-end results 7Health News:Westaim announces 2008 year-end results 8Health News:Westaim announces 2008 year-end results 9Health News:Westaim announces 2008 year-end results 10Health News:Westaim announces 2008 year-end results 11Health News:Westaim announces 2008 year-end results 12Health News:Social Class, Gender Won't Shield Smokers from Harm 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 3Health News:Research Brings New Hope to Multiple Sclerosis Patients 2
... German Craftsmanship have produced the ... world. Ocutek® now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
... integrated neck. Piston assembly fits into ... spring to recoil back to ready ... into precision milled cavity in platform. ... - 9.0mm. Designed for the preparation ...
Medicine Products: